A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2646 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-03

Study Completion Date

2023-03-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

NCT05142553

COVID-19 SARS-CoV-2 Acute Respiratory Disease

COMPLETED PHASE2

Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

NCT05305573

COVID-19 SARS-CoV-2 Acute Respiratory Disease

COMPLETED PHASE2

Safety and Immunogenicity of a Booster Vaccination with an Adapted Vaccine

NCT06181292

SARS-CoV2 Infection

COMPLETED PHASE2/PHASE3

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

NCT05303402

SARS CoV 2 Infection

COMPLETED PHASE2/PHASE3

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

NCT00354861

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 SARS-CoV-2 Acute Respiratory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: COVID-19 Vaccine HIPRA 40 ug/dose

COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA

Group Type EXPERIMENTAL

COVID-19 Vaccine 40 ug/dose

Intervention Type BIOLOGICAL

Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 Vaccine 40 ug/dose

Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, ≥ 16 years old at Day 0.
* Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
* Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
* If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
* Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
* Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
* Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
* Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
* Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
* Male participants must refrain from donating sperm for at least 28 days after day 0.

Exclusion Criteria

* History of anaphylaxis to any prior vaccine.
* Previous severe SARS-CoV-2 infections that required \>24 hous of hospitalisation.
* Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
* Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
* Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
* Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
* Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
* Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
* Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
* Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
* Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
* Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
* Chronic or recurrent administration of systemic immunosuppressant medication.
* Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
* Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
* Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
* Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
* Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes